CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.
Whether your patients prefer infusions that take less than an hour or fewer needlesticks, CUVITRU [Immune Globulin Subcutaneous (Human)] 20% Solution is the SCIG of choice with administration that can be customized to meet their individual needs.1,2
The median duration of once-weekly infusions was <1 hour (0.95 hours; range: 0.2-6.4 hours) in the North American clinical study.
84.9% of infusions (N=4314) were administered using only 1 or 2 infusion sites (18.5%=1 site; 66.4%=2 sites) in the North American clinical study.
Patients who had received IVIG previously reported that CUVITRU fit better into their schedules and was more convenient than IVIG infusion.†
*If a patient is 75 kg (165 lbs) and was prescribed 36 g of IVIG per month, you could switch your patient to 12 g of CUVITRU weekly. After the first 2 infusions, subsequent infusions of CUVITRU could be completed in 15 mins at a rate of 60 mL/h/site using 4 sites simultaneously.
†CUVITRU was shown to significantly improve patient quality of life in terms of Convenience (TSQM-9 difference 11.11; P<0.001) and Treatment Interference (LQI difference 1.50; P=0.008) when compared to IVIG treatment.
See how CUVITRU is administered.
Watch the video to learn more about CUVITRU administration.
View examples of 3 patients’ infusion sites from pre-infusion to 48 hours after.
Volume infused per physician guidance based on patient’s specific clinical condition. It may be different for other patients.
Patient No. 1
Male, age 59
Patient No. 2
Male, age 16
Explore administration parameter combinations based on needlesticks and infusion frequency, plus learn about the proper ancillary supplies.Infusion Calculator & Ancillary Supplies